“Making TauRx’s groundbreaking drug HMTM# accessible
to patients with Alzheimer's Disease under Named Patient Program”
Immuno Cure’s Anti-Δ42PD1 Antibody Project Awarded HKSAR Government’s RAISe+ Scheme Funding
Learn MorePoredeen Appoints ICB as Exclusive Named Patient ProgramManager for HMTM# in Hong Kong and Macau
Immuno Cure Completed US$12M First Close of Series A Financing, led by AEF GBA Fund managed by Gobi Partners GBA
Closed the US$12 million tranche in the US$27 million Series A fundraising round. Led by the AEF Greater Bay Area Fund that Gobi Partners GBA manages, this round will be used to accelerate the development of DNA vaccines and antibodies, as well as to prepare for an initial public offering (“IPO”) in Hong Kong.
Immuno Cure Kicks off Phase IIa Clinical Trial in Hong Kong
The initiation of a Phase IIa clinical trial of ICCOV, a COVID-19 DNA vaccine candidate. The clinical trial is initiated by Immuno Cure in collaboration with the University of Hong Kong (“HKU”) and will be conducted in Gleneagles Hospital Hong Kong.
Immuno Cure kick off Phase I Clinical Trial in Shenzhen
A significant step for developing our PD-1-Enhanced DNA Vaccine against HIV/AIDS
Immuno Cure appoints new CFO
Strengthening of executive management team to propel growth strategy